GlassScriptPhysician profile
John A Siedlecki
NPI 1316986664
$2,685.38
in general payments reported to CMS, 2019-2025
34 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $293 · 2021: $295 · 2022: $167 · 2023: $622 · 2024: $330 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.03 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $453.46 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $238.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $190.59 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $172.52 | 2023-2025 | |
| Amarin Pharma, INC. | $169.10 | 2019-2021 | |
| Amgen INC. | $137.00 | 2019-2024 | Otezla, Repatha, Evenity |
| Actelion Pharmaceuticals US, INC. | $93.04 | 2023-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $92.15 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $77.15 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $44.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.05 | 2019-2020 | |
| Boston Scientific Corporation | $35.21 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.33 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $28.37 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $27.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.42 | 2019-2021 | |
| Shire North American Group INC | $24.71 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.52 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $23.13 | 2019-2020 | |
| Allergan, INC. | $22.42 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.51 | 2021 | |
| Esperion Therapeutics, INC. | $20.60 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.42 | 2022 | |
| Sanofi Pasteur INC. | $20.24 | 2019 | |
| Dexcom, INC. | $20.09 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $19.22 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $18.77 | 2019 | |
| Biogen, INC. | $18.34 | 2023 | Spinraza |
| Phadia US INC. | $17.71 | 2020 | |
| Eisai INC. | $16.99 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.11 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Siedlecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.